MaaT Pharma announced on 9/18/19 the presentation of the analysis of MaaT Pharma’s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma’s proprietary big data analysis platform, GutPrint. The results of the study form the foundation of MaaT Pharma’s approach to create standardized and reproducible high diversity microbiome therapeutics to treat life-threatening diseases. MaaT Pharma’s Bioinformatics Manager, Lilia Boucinha, Ph.D. presented the data at the 2018 European Molecular Biology Organization (EMBO) Symposium The Human Microbiome, being held from September 16 – 19, 2018 at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.

MaaT CEO, Herve Affagard said, “Alterations in the microbiome, also called dysbiosis, have been implicated in a wide-range of diseases, and re-establishing its function has been scientifically and clinically validated as a therapeutic approach. We have developed our lead biotherapeutic product, MaaT013, based on our fundamental belief that high microbial species richness and diversity are critical to achieving therapeutic impact. The results we presented today, clearly demonstrate our capabilities to produce a reproducible high diversity cGMP product and we look forward to further evaluating MaaT013 in our ongoing Phase 2 trial in acute Graft-versus-Host Disease patients.”

In the presented study MaaT Pharma’s proprietary biotherapeutic MaaT013 was evaluated in comparison to a single donor approach using MaaT Pharma’s proprietary and validated big data analysis platform GutPrint. In comparison to single donor samples, MaaT013 showed significantly increased diversity. Most importantly, diversity within the sample batches was less variable and a greater homogeneity between batches was observed compared to single donor samples. Furthermore, the analysis of the MaaT013 samples showed that there was a 58% increase in the number of microbes (richness) compared to single-donor-based FMT products and less than 5% of Proteobacteria, which are known to include pro-inflammatory species. Taken together, these data strongly highlight MaaT Pharma’s capabilities to produce a cGMP high diversity drug product for clinical evaluation.